Table 1. Establishment of transplantable xenograft tumor lines from patient tumors.
| Patient (age/gender) | Pathologic diagnosis | Pathologic stage/grading | Neodajuvant chemotherapy | Source of tissue graft | Xenograft Model | Establishment of xenograft tumor line | Doubling time of xenograft tumor line |
|---|---|---|---|---|---|---|---|
| 53/male | UC | pT2N0Mx/G2 | Gemcitabine/Cisplatin | rCx | LTL392 | + | 11 days |
| 53/male | UC | pT1N0Mx/G2 | - | rCx | LTL480 | – | 9 days |
| 63/male | UC | pT3bN2Mx/G3 | - | rCx | LTL488 | + | 9 days |
| 72/male | SCC | pT2bN0Mx/G3 | - | rCx | LTL489 | + | 10 days |
| 67/male | UC | pT4bN0Mx/G3 | Gemcitabine/Cisplatin | rCx | LTL490 | + | 4 days |
| 73/male | UC | pT4bN3Mx/G3 | Gemcitabine/Carboplatin | rCx | LTL524 | + | 5 days |
| 70/male | UC | pT4aN3Mx/G3 | - | rCx | LTL543 | + | 9 days |
Pathological staging according to the TNM Classification of Malignant Tumours (7th Edition; 2009).
UC = urothelial carcinoma; SCC = squamous cell carcinoma.